The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010. GlobalData analysis suggests that the global HF therapeutics market will grow at a high CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696 during the forecast period.

1. Heart Failure (HF) Therapeutics - Pipeline Assessment and Market Forecasts to
2018
Published: November 2011
No. of Pages: 105
Price: $ 3500
GlobalData, the Industry analysis specialist, has released its new report, “Heart Failure (HF)
Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an
essential source of information on the global Heart Failure therapeutics market, and
provides analysis of a number of key areas. The report identifies the key trends shaping and
driving the global Heart Failure therapeutics market and provides insights into the current
competitive landscape and emerging companies expected to significantly alter the market
positioning of current market leaders. Most importantly, the report provides valuable
insights into the pipeline products within the global Heart Failure sector. This report is built
using data and information sourced from proprietary databases, primary and secondary
research and in-house analysis by GlobalData’s team of industry experts.
The global Heart Failure (HF) therapeutics market valued at $3,269.0m in 2005, and grew
at a Compound Annual Growth Rate (CAGR) of 4.5% to reach $4,068.5m in 2010.
GlobalData analysis suggests that the global HF therapeutics market will grow at a high
CAGR of 2.5% over the next eight years, to reach $5,104.1m by 2018. This growth will be
primarily attributed due to the expected launch of novel, therapies relaxin and LCZ696
during the forecast period. Relaxin is expected to be launched in late 2014 and LCZ696 in
2015. An increase in the treatment seeking population due to an increase in the life
expectancy and increasing awareness leading to diagnosis at an early stage will also drive
the HF therapeutics market. Apart from these the HF therapeutics market will be driven by
the increases in aging population which are more susceptible towards Acute Heart Failure
(AHF). The current competition in the HF therapeutics market is weak, primarily dominated
by generic drugs such as milirinone, dobutamine, digoxin, Coreg (carvedilol), and Altace
(ramipril). Only Diavon (valsartan) and Natrecor (nesiritide) are the two branded product
which are expected to lose patents in 2012 and 2014 respectively.
Scope
The report provides information on the key drivers and challenges of the Heart Failure
therapeutics market. Its scope includes -
- Annualized seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan)
Heart Failure therapeutics market revenue data for 2005–2010, and 2011–2018.

2. - The late stage pipeline has molecules which would affect progression of HF, known as
renin inhibitor, Angiotensin receptor neprilysin (ANRI) inhibitor and vasodilators in acute
case of heart failure. The other promising drugs in the HF developmental pipeline in terms
of mechanism of action include a stem cell therapy, angiotensin converting enzyme
inhibitor, aldosterone antagonist, natriuretic peptide receptor agonist, and glucagon-like
peptide 1 agonist.
- Analysis of the current and future competition in the key countries of the Heart Failure
therapeutics market. Novartis, Amgen, Cardiokline, Bayer, Nile Therapeutics, Cytokinetics,
and GlaxoSmithKline are the key players, they are key market players, is covered in this
section.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization,
unmet needs and the implications for the Heart Failure therapeutics market.
- Analysis of key recent licensing and partnership agreements in Heart Failure therapeutics
market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design in-licensing and out-licensing strategies through a review of pipeline
products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
Heart Failure therapeutics market.
- Increase revenue through an understanding of the key trends, innovative products and
technologies, market segments and companies likely to affect the global Heart Failure
therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize sales and marketing efforts by identifying the market categories and segments
that present maximum opportunities for consolidations, investments and strategic
partnerships.
- What’s the next big thing in the global Heart Failure therapeutics market landscape? –
Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7

3. 2 Heart Failure (HF) Therapeutics: Executive Summary 9
2.1 The HF Therapeutics Market Shows Significant Growth Until 2018 9
2.2 Current HF Therapeutics Market is Weak and is Dominated by Generics 10
2.3 Strong Pipeline Candidates Expected to Enter the Market, To Provide Better Treatment
Option 11
2.4 Unmet Need Remains Unaddressed 11
3 Heart Failure (HF) Therapeutics: Introduction 13
3.1 Overview 13
3.2 Etiology 14
3.3 Pathophysiology 17
3.4 Epidemiology & Prognosis 19
3.5 Symptoms 19
3.6 Diagnosis 20
3.7 Treatment and Management Pattern 27
3.7.1 Pharmacological Therapies 27
3.7.2 Goals of treatment of the patients with HF 28
3.8 GlobalData Report Guidance 31
4 HF Therapeutics: Market Characterization 32
4.1 HF Therapeutics Market Size (2005-2010) – Global 32
4.2 HF Therapeutics Market Forecast (2010-2018) – Global 33
4.3 HF Therapeutics Market Size (2005-2010): The US 34
4.4 HF Therapeutics Market Forecast (2010-2018): The US 36
4.5 HF Therapeutics Market (2005-2010): France 37
4.6 HF Therapeutics Market Forecast (2010-2018): France 37
4.7 HF Therapeutics Market (2005-2010): Germany 38
4.8 HF Therapeutics Market Forecast (2010-2018): Germany 39
4.9 HF Therapeutics Market (2005-2010): Italy 40
4.10 HF Therapeutics Market Forecast (2010-2018): Italy 41
4.11 HF Therapeutics Market (2005-2010): Spain 42
4.12 HF Therapeutics Market Forecast (2010-2018): Spain 43
4.13 HF Therapeutics Market (2005-2010): The UK 44
4.14 HF Therapeutics Market Forecast (2010-2018): The UK 45
4.15 HF Therapeutics Market (2005-2010): Japan 46
4.16 HF Therapeutics Market Forecast (2010-2018): Japan 47
4.17 Drivers and Barriers for the HF Therapeutics Market 49
4.17.1 Drivers for the HF Therapeutics Market 49
4.17.2 Barriers for the HF Therapeutics Market 49
4.18 Opportunity and Unmet Need Analysis 50
4.19 Key Takeaway 51
5 HF Therapeutics: Competitive Assessment 52
5.1 Overview 52
5.2 Strategic Competitor Assessment 52
5.3 Product Profile for the Major Marketed Products in the HF Therapeutics Market 54
5.3.1 Natrecor (nesiritide) 54
5.3.2 Primacor (milrinone lactate) 55
5.3.3 Coreg (Carvedilol) 56
5.3.4 Altace (ramipril) 57
5.3.5 Diovan (Valsartan) 58
5.4 Key Takeaway 60
6 HF Therapeutics: Pipeline Assessment 61

4. 6.1 Overview 61
6.2 Strategic Pipeline Assessment 61
6.3 HF Therapeutics Pipeline – Pipeline by Phases of Development 62
6.3.1 HF Therapeutics – Phase III Pipeline 62
6.3.2 HF Therapeutics – Phase II Pipeline 63
6.3.3 HF Therapeutics – Phase I Pipeline 63
6.3.4 HF Therapeutics – Preclinical Pipeline 64
6.3.5 HF Therapeutics – Discovery Pipeline 64
6.4 HF Therapeutics Market – Clinical Pipeline by Mechanism of Action 64
6.5 Technology Trends Analytical Framework 65
6.6 HF Therapeutics – Promising Drugs Under Clinical Development 67
6.7 Molecule Profile for Promising Drugs Under Clinical Development 68
6.7.1 Relaxin (RLX030) 68
6.7.2 LCZ696 69
6.7.3 Lixivaptan 69
6.7.4 Tekturna/Rasilez (aliskiren) 70
6.8 Key Takeaway 71
7 HF Therapeutics: Clinical Trials Mapping 72
7.1 Clinical Trials by Region/Country (the US, EU5, and Japan) 72
7.2 Clinical Trials by Phase 73
7.3 Clinical Trials by Trial Status 74
7.4 Clinical Trials by Overall Sponsors 75
7.5 Prominent Sponsors 76
7.6 Key Companies Participating in Therapeutics Clinical Trials 77
8 HF Therapeutics: Stategic Assessment 79
8.1 Key Events Impacting the Future Market 79
8.2 HF Therapeutics: Implications for Future Market Competition 80
9 HF Therapeutics: Future Players 82
9.1 Introduction 82
9.2 Company Profiles 83
9.2.1 Novartis AG. 83
9.2.2 Amgen Inc. 85
9.2.3 Cardiokine, Inc 87
9.2.4 Bayer AG. 88
9.2.5 Nile Therapeutics, Inc.. 90
9.2.6 Cardioxyl Pharmaceuticals, Inc 91
9.2.7 Cytokinetics, Inc 92
9.2.8 GlaxoSmithKline plc 94
9.2.9 Trevena, Inc. 95
10 HF Therapeutics: Licensing and Partnership Deals 97
11 HF Therapeutics: Appendix 98
11.1 Market Definitions 98
11.2 Acronyms 98
11.3 Research Methodologyy 99
11.3.1 Coverage 99
11.3.2 Secondary Research 100
11.3.3 Forecasting 100
11.3.4 Primary Research 103
11.3.5 Expert Panel Validation 104
11.4 Contact Us 104

5. 11.5 Disclaimer 104
11.6 Bibliography 105
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog